Clinical use of ivabradine in the acute coronary syndrome: A systematic review and narrative synthesis of current evidence.

ABSTRACT: Heart rate (HR) lowering during acute coronary syndrome (ACS) is beneficial as it reduces myocardial oxygen consumption. However, the role of ivabradine as an HR-lowering agent in the setting of ACS is not clear. We aimed to systematically review and synthesize the current evidence on the role of ivabradine use in the ACS. A systematic review was conducted for eligible randomized clinical trials and quasi-experimental studies, between 2009 and 2020, that investigated the use of ivabradine in ACS. Various clinical endpoints were evaluated such as major adverse cardiovascular events, efficacy in HR control, impact on left ventricular (LV) dimensions and function, and overall safety. Eleven publications were included encompassing a total of 1833 patients. The mean age of the examined cohort w

SUBMITTER: Borovac JA 

PROVIDER: S-EPMC10978351 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature